Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1966 1
1971 1
1975 10
1976 9
1977 6
1978 6
1979 6
1980 14
1981 17
1982 19
1983 35
1984 45
1985 45
1986 41
1987 55
1988 55
1989 81
1990 80
1991 95
1992 92
1993 108
1994 120
1995 138
1996 136
1997 144
1998 154
1999 166
2000 187
2001 207
2002 228
2003 273
2004 277
2005 293
2006 310
2007 331
2008 345
2009 392
2010 416
2011 426
2012 450
2013 457
2014 509
2015 544
2016 601
2017 648
2018 656
2019 693
2020 840
2021 877
2022 889
2023 898
2024 337

Text availability

Article attribute

Article type

Publication date

Search Results

12,080 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory malignant neoplasm"
Page 1
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Connors JM, et al. Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. Nat Rev Dis Primers. 2020. PMID: 32703953 Review.
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. ...Although uncommon, HL remains a crucial test case for progress in cancer treatment. HL was among the first systemic neop …
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour micr …
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G. Garcia-Manero G. Am J Hematol. 2023 Aug;98(8):1307-1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8. Am J Hematol. 2023. PMID: 37288607 Review.
Under this classification, MDS is now termed myelodysplastic neoplasms. RISK-STRATIFICATION: Prognosis of patients with MDS can be calculated using a number of scoring systems. All these scoring systems include analysis of peripheral cytopenias, …
Under this classification, MDS is now termed myelodysplastic neoplasms. RISK-STRATIFICATION: Prognosis of patients with MDS can be ca …
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S, Kennedy JJ, Ivey RG, Murillo OD, Hosseini N, Song X, Petralia F, Calinawan A, Savage SR, Berry AB, Reva B, Ozbek U, Krek A, Ma W, da Veiga Leprevost F, Ji J, Yoo S, Lin C, Voytovich UJ, Huang Y, Lee SH, Bergan L, Lorentzen TD, Mesri M, Rodriguez H, Hoofnagle AN, Herbert ZT, Nesvizhskii AI, Zhang B, Whiteaker JR, Fenyo D, McKerrow W, Wang J, Schürer SC, Stathias V, Chen XS, Barcellos-Hoff MH, Starr TK, Winterhoff BJ, Nelson AC, Mok SC, Kaufmann SH, Drescher C, Cieslik M, Wang P, Birrer MJ, Paulovich AG. Chowdhury S, et al. Cell. 2023 Aug 3;186(16):3476-3498.e35. doi: 10.1016/j.cell.2023.07.004. Cell. 2023. PMID: 37541199 Free PMC article.
We identified a 64-protein signature that predicts with high specificity a subset of HGSOCs refractory to initial platinum-based therapy and is validated in two independent patient cohorts. ...These clusters may represent different mechanisms of refractoriness …
We identified a 64-protein signature that predicts with high specificity a subset of HGSOCs refractory to initial platinum-bas …
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma.
Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Chang Y, et al. Int J Mol Sci. 2020 Oct 31;21(21):8165. doi: 10.3390/ijms21218165. Int J Mol Sci. 2020. PMID: 33142892 Free PMC article. Review.
When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. ...Recently, new prognostic models, includi …
When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) …
Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
He H, Li Z, Lu J, Qiang W, Jiang S, Xu Y, Fu W, Zhai X, Zhou L, Qian M, Du J. He H, et al. Clin Transl Med. 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757. Clin Transl Med. 2022. PMID: 35297204 Free PMC article.
We tried to dissect this disease and identify novel biomarkers for patient stratification and treatment outcome prediction by applying single-cell technology. METHODS: We performed single-cell RNA sequencing (scRNA-seq) and variable-diversity-joining regions-targeted seque …
We tried to dissect this disease and identify novel biomarkers for patient stratification and treatment outcome prediction by applyin …
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Rivera F, et al. Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8. doi: 10.1586/era.09.113. Expert Rev Anticancer Ther. 2009. PMID: 19828002
In the cetuximab arm of this study, a significant improvement in the overall survival (the main objective), progression-free survival and response rate were observed. The quality of life analyses (QLQ-C30 and QLQ-H&N35) showed no significant differences in most of the …
In the cetuximab arm of this study, a significant improvement in the overall survival (the main objective), progression-free survival and re …
Serum Inflammation-based Scores in Endocrine Tumors.
Marques P, de Vries F, Dekkers OM, Korbonits M, Biermasz NR, Pereira AM. Marques P, et al. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3796-e3819. doi: 10.1210/clinem/dgab238. J Clin Endocrinol Metab. 2021. PMID: 33837783 Free PMC article. Review.
CONTEXT: Serum inflammation-based scores reflect systemic inflammatory response and/or patients' nutritional status, and may predict clinical outcomes in cancer. ...CONCLUSIONS: In this review, we summarize the current knowledge on the different serum inflammation-b …
CONTEXT: Serum inflammation-based scores reflect systemic inflammatory response and/or patients' nutritional status, and may predi …
Drug Resistance in Non-Hodgkin Lymphomas.
Klener P, Klanova M. Klener P, et al. Int J Mol Sci. 2020 Mar 18;21(6):2081. doi: 10.3390/ijms21062081. Int J Mol Sci. 2020. PMID: 32197371 Free PMC article. Review.
Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. ...Despite immense progress, our effort to control or even eradicate malignant lymphoma clones …
Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes dur …
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Fukuoka M, et al. J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13. J Clin Oncol. 2011. PMID: 21670455 Clinical Trial.
The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differences observed for PFS in the EGFR mutation-positive subgroup were not apparent for OS. ...
The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differenc …
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play/Karnofsky Performance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg/kg every 3 weeks. .. …
Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play/K …
12,080 results
You have reached the last available page of results. Please see the User Guide for more information.